Treatment of hepatic coma and hepatorenal syndrome. Mechanism of action of L-dopa and aramine.
D000328:Adult; D001923:Brain Chemistry; D002247:Carbon Isotopes; D002302:Cardiac Output / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy*; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008680:Metaraminol / Q000627:therapeutic use*; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009655:Octopamine / Q000032:analysis / Q000652:urine; D010627:Phenethylamines / Q000032:analysis; D012436:S-Adenosylmethionine; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D013569:Synapses
D002247:Carbon Isotopes; D018377:Neurotransmitter Agents; D010627:Phenethylamines; D009655:Octopamine; D004295:Dihydroxyphenylalanine; D012436:S-Adenosylmethionine; D008680:Metaraminol